 | EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT. | 4CPS-001 |
 | SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE | 4CPS-002 |
 | EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW | 4CPS-003 |
 | TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL | 4CPS-004 |
 | SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT | 4CPS-005 |
 | COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN | 4CPS-006 |
 | TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE. | 4CPS-007 |
 | DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS? | 4CPS-008 |
 | Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-009 |
 | DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-010 |
 | CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL | 4CPS-011 |
 | PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY | 4CPS-012 |
| TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY. | 4CPS-013 |
 | COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS | 4CPS-014 |
 | ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT | 4CPS-015 |
 | PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS | 4CPS-016 |
 | REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. | 4CPS-017 |
 | EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS | 4CPS-018 |
 | QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS | 4CPS-019 |
 | TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS. | 4CPS-020 |
| EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY | 4CPS-021 |
 | ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION | 4CPS-022 |
 | TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY | 4CPS-023 |
 | COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION | 4CPS-024 |
| FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’ | 4CPS-025 |
 | EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS | 4CPS-026 |
 | COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA. | 4CPS-027 |
| DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY | 4CPS-028 |
 | ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES | 4CPS-029 |
 | IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES | 4CPS-030 |
 | THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES | 4CPS-031 |
| THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS – A RETROSPECTIVE ANALYSIS | 4CPS-032 |
 | EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE | 4CPS-033 |
 | ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19 | 4CPS-034 |
 | ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE | 4CPS-035 |
 | SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT | 4CPS-036 |
 | INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS | 4CPS-037 |
 | CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY | 4CPS-038 |
 | CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS. | 4CPS-039 |
 | ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS | 4CPS-040 |
 | ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT | 4CPS-041 |
 | OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT | 4CPS-042 |
 | DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS | 4CPS-043 |
 | EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT | 4CPS-044 |
| ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE | 4CPS-045 |
| A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT | 4CPS-046 |
 | IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY | 4CPS-047 |
 | ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN | 4CPS-048 |
 | TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS | 4CPS-049 |
 | ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 4CPS-050 |
| IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS | 4CPS-051 |
 | LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH) | 4CPS-052 |
 | KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT | 4CPS-053 |
 | USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT. | 4CPS-054 |
 | EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER. | 4CPS-055 |
| A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE | 4CPS-056 |
 | SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT. | 4CPS-057 |
 | SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA | 4CPS-058 |
| EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS | 4CPS-059 |
 | EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER | 4CPS-060 |
 | APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-061 |
 | EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT | 4CPS-062 |
 | USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING | 4CPS-063 |
 | EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN. | 4CPS-064 |
| SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT | 4CPS-065 |
 | BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL | 4CPS-066 |
 | A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY | 4CPS-067 |
 | CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS | 4CPS-068 |
 | EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC | 4CPS-069 |
 | THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS | 4CPS-070 |
| IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS | 4CPS-071 |
 | REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL | 4CPS-072 |
 | ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM | 4CPS-073 |
 | EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL | 4CPS-074 |
 | PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS | 4CPS-075 |
 | EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA. | 4CPS-076 |
 | CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE | 4CPS-077 |
 | ASSESSMENT OF THE QUALITY OF A HOSPITAL’S CLINICAL TRIAL INITIATION VISIT | 4CPS-078 |
 | COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION | 4CPS-079 |
 | OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE. | 4CPS-080 |
| EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV | 4CPS-081 |
 | MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN | 4CPS-082 |
 | CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING | 4CPS-083 |
 | EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION | 4CPS-084 |
| PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT | 4CPS-085 |
| COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. | 4CPS-086 |
 | PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS | 4CPS-087 |
 | CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB | 4CPS-088 |
 | CURRENT STATUS OF HEPATITIS C VIRUS INFECTION | 4CPS-089 |
| A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES | 4CPS-090 |
 | WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST | 4CPS-091 |
 | STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS | 4CPS-092 |
 | POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA | 4CPS-093 |
 | ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT | 4CPS-094 |
 | INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES | 4CPS-095 |
| EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS | 4CPS-096 |
 | COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS. | 4CPS-097 |
 | NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS | 4CPS-098 |
 | NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL | 4CPS-099 |
 | VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST | 4CPS-100 |
 | CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE | 4CPS-101 |
 | DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT | 4CPS-102 |
 | PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT | 4CPS-103 |
 | ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA | 4CPS-104 |
 | CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA | 4CPS-105 |
 | BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD | 4CPS-106 |
 | EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN | 4CPS-107 |
 | PATIENT AND PHYSICIANS’S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL | 4CPS-108 |
 | THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA | 4CPS-109 |
 | ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS | 4CPS-110 |
 | IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE | 4CPS-111 |
 | SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC | 4CPS-112 |
 | ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL | 4CPS-113 |
 | DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT | 4CPS-114 |
 | DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING | 4CPS-115 |
 | THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW | 4CPS-116 |
 | USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS | 4CPS-117 |
 | HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL | 4CPS-118 |
 | PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 4CPS-119 |
 | ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT» | 4CPS-120 |
 | ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS | 4CPS-121 |
 | CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE | 4CPS-122 |
 | CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS | 4CPS-123 |
 | EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL | 4CPS-124 |
 | PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION | 4CPS-125 |
 | LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL | 4CPS-126 |
 | PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION | 4CPS-127 |
 | CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA. | 4CPS-128 |
 | REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER | 4CPS-129 |
 | EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-130 |
 | SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS | 4CPS-131 |
 | ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION | 4CPS-132 |
 | SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-133 |
| PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 – 2021 | 4CPS-134 |
 | MELANOMA ADJUVANT THERAPY: from trials to clinical practice215 | 4CPS-135 |
 | STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE | 4CPS-136 |
 | EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL | 4CPS-137 |
 | USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES | 4CPS-138 |
 | THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ? | 4CPS-139 |
| MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY | 4CPS-140 |
 | PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE | 4CPS-141 |
 | EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE | 4CPS-142 |
 | CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART. | 4CPS-143 |
 | EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION | 4CPS-144 |
 | CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST | 4CPS-145 |
 | ‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION | 4CPS-146 |
 | REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC) | 4CPS-147 |
| USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION | 4CPS-148 |
 | PAIN MANAGEMENT IN MENTAL HEALTH. | 4CPS-149 |
 | THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT | 4CPS-150 |
 | ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER | 4CPS-151 |
 | PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT. | 4CPS-152 |
 | OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST | 4CPS-153 |
 | IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW | 4CPS-154 |
 | CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS | 4CPS-155 |
 | ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL | 4CPS-156 |
 | COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL | 4CPS-157 |
 | IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT | 4CPS-158 |
 | ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION | 4CPS-159 |
 | REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS | 4CPS-160 |
 | NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE | 4CPS-161 |
 | TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION. | 4CPS-162 |
 | CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY | 4CPS-163 |
 | ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE. | 4CPS-164 |
 | ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL. | 4CPS-165 |
 | IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME | 4CPS-166 |
 | CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER | 4CPS-167 |
 | RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE | 4CPS-168 |
 | PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES | 4CPS-169 |
| THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN | 4CPS-170 |
 | METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE | 4CPS-171 |
 | BRODALUMAB’S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE | 4CPS-172 |
 | EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES | 4CPS-173 |
| EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS | 4CPS-174 |
 | SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS | 4CPS-175 |
 | EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS | 4CPS-176 |
 | OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT | 4CPS-177 |
 | DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-178 |
| REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION | 4CPS-179 |
 | VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION | 4CPS-180 |
 | FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL | 4CPS-181 |
 | EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE | 4CPS-182 |
 | EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING | 4CPS-183 |
 | WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY? | 4CPS-184 |
| COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY | 4CPS-185 |
 | EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-186 |
 | PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-187 |
 | QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT | 4CPS-188 |
 | ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES | 4CPS-189 |
 | ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT? | 4CPS-190 |
 | IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS | 4CPS-191 |
 | ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY | 4CPS-192 |
 | SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME | 4CPS-193 |
 | BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION | 4CPS-194 |
 | E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS | 4CPS-195 |
 | POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV | 4CPS-196 |
 | CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE? | 4CPS-197 |
 | ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL | 4CPS-198 |
 | PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN | 4CPS-199 |
 | SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS | 4CPS-200 |
 | PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON | 4CPS-201 |
 | THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT | 4CPS-202 |
 | ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW | 4CPS-203 |
 | NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY | 4CPS-204 |
 | PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT | 4CPS-205 |
 | EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS | 4CPS-206 |
| PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA | 4CPS-207 |
 | TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES | 4CPS-208 |
 | EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS. | 4CPS-209 |
 | EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL | 4CPS-210 |
| DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS’S KNOWLEDGE | 4CPS-211 |
 | SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS | 4CPS-212 |
 | CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT | 4CPS-213 |
 | REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER | 4CPS-214 |
 | DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS. | 4CPS-215 |
| OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH’S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT | 4CPS-216 |
 | THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION | 4CPS-217 |
| TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS | 4CPS-218 |
 | AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT | 4CPS-219 |
 | COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS. | 4CPS-220 |
 | ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE | 4CPS-221 |
 | HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA | 4CPS-222 |
 | BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS | 4CPS-223 |
 | IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS | 4CPS-224 |
 | HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs) | 4CPS-225 |
 | CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS? | 4CPS-226 |
 | REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN | 4CPS-227 |
 | HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS | 4CPS-228 |
 | THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST | 4CPS-229 |
 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA | 4CPS-230 |
| EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS | 4CPS-231 |
 | COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-232 |
 | PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE | 4CPS-233 |
 | DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA | 4CPS-234 |
| IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS | 4CPS-235 |
 | LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV | 4CPS-236 |
 | HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS. | 4CPS-237 |
 | PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT. | 4CPS-238 |
 | POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS | 4CPS-239 |
| FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | 4CPS-240 |
 | FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL | 4CPS-241 |
 | ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING. | 4CPS-242 |
 | DELAYED HIV TREATMENT AND FACTORS ASSOCIATED | 4CPS-243 |
 | ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS | 4CPS-244 |
 | PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS | 4CPS-245 |
 | TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT | 4CPS-246 |
 | INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY | 4CPS-247 |
 | THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS | 4CPS-248 |
 | RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS. | 4CPS-249 |
 | EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT | 4CPS-250 |
 | HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN | 4CPS-251 |
 | OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT | 4CPS-252 |
| DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL | 4CPS-253 |
 | DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE | 4CPS-254 |
 | ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY | 4CPS-255 |
 | ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES | 4CPS-256 |
 | PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY | 4CPS-257 |
 | PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL | 4CPS-258 |
 | MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT | 4CPS-259 |
 | PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA | 4CPS-260 |
| ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION. | 4CPS-261 |
 | A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY | 4CPS-262 |
 | THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP) | 4CPS-263 |